注射用益氣復(fù)脈（凍干）臨床用于冠心病勞累型心絞痛屬氣陰兩虛證，以及冠心病導(dǎo)致的心功能不全等心血管系統(tǒng)疾病，對(duì)改善氣陰兩虛型的心力衰竭的心功能、調(diào)節(jié)血壓療效顯著。綜述近10年來(lái)注射用益氣復(fù)脈（凍干）改善心功能、增強(qiáng)心肌收縮力、調(diào)節(jié)心肌能量代謝及調(diào)整血壓的藥理作用及機(jī)制［其作用機(jī)制包括抑制核轉(zhuǎn)錄因子-κB、絲裂原活化蛋白激酶（MAPK）降低心肌損傷、提高T-ATPase、Ca²⁺，Mg²⁺-ATPase和Na⁺，K⁺-ATPase酶活力改善心肌能量代謝，降低腎上腺素β受體激動(dòng)藥物異丙腎上腺素及相關(guān)血管內(nèi)皮因子血管緊張素II（AngII）影響］，以期為后續(xù)的深入研究提供參考，為臨床合理用藥提供數(shù)據(jù)支持。

Yiqi Fumai Lyophilized Injection (YQFM) is clinically used in coronary heart disease fatigue angina pectoris which is a syndrome of Qi and Yin deficiency, and cardiovascular diseases such as cardiac dysfunction caused by coronary heart disease. It can improve the heart function of heart failure with Qi and Yin deficiency and regulate the blood pressure significantly. It was reviewed the main pharmacological effects of YQFM in recent years to improve cardiac function, regulate myocardial energy metabolism and adjust blood pressure and related mechanisms of action include enhanced the cardiac function by inhibiting the phosphorylation of NF-κB and mitogen-activated protein kinase (MAPK) signaling pathway; enhanced the activity of T-ATPase, Ca²⁺, Mg²⁺-ATPase and Na⁺, K⁺-ATPase to regulate myocardial energy metabolism. To reduce the effects of epinephrine β -agonist isoproterenol and the related vascular endothelial factor angiotensin II (AngII), in order to provide reference for further research and improvement of subsequent products, and provide data support for clinical medicatio.

R285.5;R286.2